AB0509 Kzr-616, a selective inhibitor of the immunoproteasome, shows a promising safety and target inhibition profile in a phase i, double-blind, single (SAD) and multiple ascending dose (MAD) study in healthy volunteers
Lickliter, J., Bomba, D., Anderl, J., Fan, A., Kirk, C.J., Wang, J.
Published in Annals of the rheumatic diseases (01.06.2018)
Published in Annals of the rheumatic diseases (01.06.2018)
Get full text
Journal Article
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors
Niewerth, Denise, Franke, Niels E, Jansen, Gerrit, Assaraf, Yehuda G, van Meerloo, Johan, Kirk, Christopher J, Degenhardt, Jeremiah, Anderl, Janet, Schimmer, Aaron D, Zweegman, Sonja, de Haas, Valerie, Horton, Terzah M, Kaspers, Gertjan J L, Cloos, Jacqueline
Published in Haematologica (Roma) (01.12.2013)
Published in Haematologica (Roma) (01.12.2013)
Get full text
Journal Article
322 Efficacy of Amanitin Conjugated Chimeric Anti-EpCAM Monoclonal Antibody in Experimental Carcinomas
Salnikov, A.V, Moldenhauer, G, Lüttgau, S, Herr, I, Anderl, J, Faulstich, H
Published in European journal of cancer (1990) (01.11.2012)
Published in European journal of cancer (1990) (01.11.2012)
Get full text
Journal Article
Strain-induced collagen denaturation is rate dependent in failure of cerebral arteries
Anderl, William J., Pearson, Noah, Converse, Matthew I., Yu, S. Michael, Monson, Kenneth L.
Published in Acta biomaterialia (01.07.2023)
Published in Acta biomaterialia (01.07.2023)
Get full text
Journal Article
POS0715 TREATMENT OF SLE PATIENTS WITH ZETOMIPZOMIB (KZR-616), A SELECTIVE INHIBITOR OF THE IMMUNOPROTEASOME, RESULTS IN CIRCULATING GENE EXPRESSION, PROTEIN LEVEL, AND IMMUNE CELL PHENOTYPIC CHANGES WITH POTENTIAL CORRELATIONS TO CLINICAL RESPONSE
Fan, A., Tuch, B., Muchamuel, T., Anderl, J., Leff, R., Henig, N., Kirk, C.
Published in Annals of the rheumatic diseases (01.06.2022)
Published in Annals of the rheumatic diseases (01.06.2022)
Get full text
Journal Article
FRI0296 Kzr-616, a selective inhibitor of the immunoproteasome, blocks the disease progression in multiple models of systemic lupus erythematosus (SLE)
Muchamuel, T., Anderl, J.L., Fan, R.A., Johnson, H.W.B., Kirk, C.J., Lowe, E.
Published in Annals of the rheumatic diseases (01.06.2018)
Published in Annals of the rheumatic diseases (01.06.2018)
Get full text
Journal Article